药明康德
(603259)
| 流通市值：2742.37亿 | | | 总市值：3272.63亿 |
| 流通股本：24.73亿 | | | 总股本：29.52亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 21,485,198,395.79 | 24,851,144,430.26 | 18,322,034,067.7 | 14,051,541,214.47 |
| 交易性金融资产 | 2,942,419,172.43 | 900,980,630.42 | 1,233,983,963.56 | - |
| 衍生金融资产 | 2,618,674 | 641,429.47 | - | 100,894,684.14 |
| 应收票据及应收账款 | 7,046,591,939.48 | 7,324,775,256.18 | 8,044,373,656.94 | 8,113,218,071.54 |
| 其中：应收票据 | 14,249,003.27 | 7,081,650.73 | 92,672,778.12 | 98,674,289.85 |
| 应收账款 | 7,032,342,936.21 | 7,317,693,605.45 | 7,951,700,878.82 | 8,014,543,781.69 |
| 预付款项 | 215,891,788.78 | 247,082,930.3 | 225,725,044.84 | 238,754,273.51 |
| 其他应收款合计 | 497,343,390.63 | 583,339,602.45 | 123,871,411.09 | 305,029,806.15 |
| 其中:应收利息 | 100,885,861.23 | 67,458,538.3 | 15,439,815.32 | 176,776,121.11 |
| 存货 | 7,151,214,786.47 | 6,491,757,171.41 | 5,399,747,062.06 | 5,347,792,758.02 |
| 合同资产 | 825,681,661.85 | 876,183,307.86 | 988,835,929.58 | 1,135,031,691.43 |
| 一年内到期的非流动资产 | 735,642,342.11 | 736,534,807.4 | 734,077,736.67 | - |
| 其他流动资产 | 1,503,368,171.42 | 1,295,623,583.19 | 1,426,171,681.73 | 1,170,486,377.86 |
| 流动资产合计 | 42,588,730,423.99 | 43,308,063,148.94 | 38,690,152,263.99 | 30,462,748,877.12 |
| 非流动资产: | | | | |
| 长期股权投资 | 1,890,460,225.96 | 2,110,305,461.34 | 2,325,547,530.62 | 2,370,173,557.65 |
| 其他非流动金融资产 | 8,504,412,209.13 | 8,707,828,279.71 | 8,943,404,353.91 | 8,660,659,670.2 |
| 固定资产 | 18,672,287,350.64 | 18,409,260,379.07 | 18,784,189,923.36 | 18,342,952,353.55 |
| 在建工程 | 6,616,940,095.95 | 6,375,357,424.72 | 5,965,794,321.58 | 6,026,413,201.93 |
| 生产性生物资产 | 1,065,099,000 | 1,045,196,000 | 1,062,969,000 | 1,096,719,000 |
| 使用权资产 | 930,348,161.05 | 969,978,832.26 | 901,030,886.55 | 1,491,572,314.82 |
| 无形资产 | 1,482,798,029.85 | 1,503,713,076.36 | 1,574,802,246.74 | 1,793,353,509.96 |
| 商誉 | 971,608,125.55 | 972,053,972.22 | 972,352,431.55 | 1,836,575,496.99 |
| 长期待摊费用 | 446,000,817.06 | 483,917,180.15 | 526,785,195.82 | 1,646,432,316.09 |
| 递延所得税资产 | 511,074,087.89 | 489,830,757.54 | 473,067,120.36 | 402,915,003.64 |
| 其他非流动资产 | 144,021,375.17 | 136,583,580.92 | 105,729,134.27 | 107,724,573.28 |
| 非流动资产合计 | 41,235,049,478.25 | 41,204,024,944.29 | 41,635,672,144.76 | 43,775,490,998.11 |
| 资产总计 | 83,823,779,902.24 | 84,512,088,093.23 | 80,325,824,408.75 | 74,238,239,875.23 |
| 流动负债: | | | | |
| 短期借款 | 5,797,353,028.01 | 4,793,461,369.34 | 1,242,689,653.78 | 2,704,989,653.78 |
| 衍生金融负债 | - | 63,067,433.45 | 202,036,417.92 | 64,242,595.44 |
| 应付票据及应付账款 | 2,158,849,287.23 | 2,218,892,853.22 | 1,764,441,417.43 | 1,998,329,644.58 |
| 其中：应付票据 | - | 28,761,600.06 | 14,380,800 | - |
| 应付账款 | 2,158,849,287.23 | 2,190,131,253.16 | 1,750,060,617.43 | 1,998,329,644.58 |
| 合同负债 | 2,227,078,534.78 | 2,349,782,750.82 | 2,251,025,010.47 | 2,471,385,961.82 |
| 应付职工薪酬 | 1,827,364,280.26 | 1,495,272,981.7 | 2,147,243,194.57 | 1,611,274,803.01 |
| 应交税费 | 1,534,061,706.82 | 1,389,298,411.71 | 1,210,636,121.99 | 950,547,330.94 |
| 其他应付款合计 | 3,198,710,213.59 | 2,803,310,510.68 | 2,789,321,889.76 | 2,855,245,818.77 |
| 其中:应付利息 | 756,890.28 | 1,334,083.73 | 26,619,858.52 | 27,969,705.3 |
| 应付股利 | 25,144,176 | 31,294,680 | - | - |
| 一年内到期的非流动负债 | 221,763,996.1 | 247,456,063.25 | 260,096,805.26 | 271,405,290.68 |
| 其他流动负债 | 3,517,369,518.75 | 3,513,262,698.15 | 3,493,083,819.15 | - |
| 流动负债合计 | 20,518,915,049.34 | 18,873,805,072.32 | 16,226,114,890.7 | 12,927,421,099.02 |
| 非流动负债: | | | | |
| 长期借款 | 904,891,240.48 | 763,298,734.83 | 2,959,508,734.83 | 2,911,138,289.87 |
| 租赁负债 | 592,095,179.22 | 625,804,852.25 | 546,560,928.62 | 1,202,535,032.59 |
| 递延收益 | 959,417,342.59 | 976,645,801.73 | 985,611,937.63 | 1,019,988,401.76 |
| 递延所得税负债 | 439,379,335.81 | 493,771,874.79 | 522,414,281.4 | 593,914,950 |
| 非流动负债合计 | 2,895,783,098.1 | 2,859,521,263.6 | 5,014,095,882.48 | 5,727,576,674.22 |
| 负债合计 | 23,414,698,147.44 | 21,733,326,335.92 | 21,240,210,773.18 | 18,654,997,773.24 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 2,872,217,205 | 2,887,992,582 | 2,887,992,582 | 2,911,927,203 |
| 资本公积 | 23,287,828,945.4 | 24,242,980,481.94 | 24,337,764,002.7 | 25,575,508,845.13 |
| 减:库存股 | 4,600,976,294.78 | 2,256,621,871.3 | 2,259,008,874.29 | 3,870,742,317.26 |
| 其他综合收益 | 268,784,721.41 | 420,991,866.81 | 300,888,716.77 | 109,148,911.82 |
| 盈余公积 | 1,436,108,602.5 | 1,357,438,183.52 | 1,357,438,183.52 | 1,023,342,127.82 |
| 未分配利润 | 36,647,745,125.5 | 35,679,601,514.14 | 32,007,640,563.67 | 29,424,362,889.87 |
| 归属于母公司股东权益合计 | 59,911,708,305.03 | 62,332,382,757.11 | 58,632,715,174.37 | 55,173,547,660.38 |
| 少数股东权益 | 497,373,449.77 | 446,379,000.2 | 452,898,461.2 | 409,694,441.61 |
| 股东权益合计 | 60,409,081,754.8 | 62,778,761,757.31 | 59,085,613,635.57 | 55,583,242,101.99 |
| 负债和股东权益合计 | 83,823,779,902.24 | 84,512,088,093.23 | 80,325,824,408.75 | 74,238,239,875.23 |
| 公告日期 | 2025-07-29 | 2025-04-29 | 2025-03-18 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |